|
1
|
Pang CH, Du W, Long J and Song LJ:
Mechanism of SEMA3B gene silencing and clinical significance in
glioma. Genet Mol Res: 15, 2016 doi: 10.4238/gmr.15017664.
|
|
2
|
Qiuju W, Liya Z, Yan S and Yuanyuan W:
Effects of miR-335-5p targeting SEMA3B on proliferation and
apoptosis of endometrial cancer cells. Shaanxi Med J. 52:798–802.
2023.
|
|
3
|
Zhang X, Klamer B, Li J, Fernandez S and
Li L: A pan-cancer study of class-3 semaphorins as therapeutic
targets in cancer. BMC Med Genomics. 13(45)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li GZ, Shen D, Li GH, Wei M, Zheng LJ, Liu
ZL, Sun RQ, Zhou SJ, Zhang ZL and Gao YC: Decreased expression of
serum semaphorin 3B is associated with poor prognosis of patients
with hepatocellular carcinoma. Exp Ther Med. 21(236)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mastrantonio R, You H and Tamagnone L:
Semaphorins as emerging clinical biomarkers and therapeutic targets
in cancer. Theranostics. 11:3262–3277. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Toledano S, Nir-Zvi I, Engelman R, Kessler
O and Neufeld G: Class-3 semaphorins and their receptors: Potent
multifunctional modulators of tumor progression. Int J Mol Sci.
20(556)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Alto LT and Terman JR: Semaphorins and
their signaling mechanisms. Methods Mol Biol. 1493:1–25.
2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Valiulyte I, Steponaitis G, Kardonaite D,
Tamasauskas A and Kazlauskas A: A SEMA3 signaling pathway-based
multi-biomarker for prediction of glioma patient survival. Int J
Mol Sci. 21(7396)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fernández-Nogueira P, Linzoain-Agos P,
Cueto-Remacha M, De la Guia-Lopez I, Recalde-Percaz L, Parcerisas
A, Gascon P, Carbó N, Gutierrez-Uzquiza A, Fuster G and Bragado P:
Role of semaphorins, neuropilins and plexins in cancer progression.
Cancer Lett. 606(217308)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen T, Li S and Wang L: Semaphorins in
tumor microenvironment: Biological mechanisms and therapeutic
progress. Int Immunopharmacol. 132(112035)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wagner W, Ochman B and Wagner W:
Semaphorin 6 Family-an important yet overlooked group of signaling
proteins involved in cancerogenesis. Cancers (Basel).
15(5536)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Meng Z, Li FL, Fang C, Yeoman B, Qiu Y,
Wang Y, Cai X, Lin KC, Yang D, Luo M, et al: The Hippo pathway
mediates Semaphorin signaling. Sci Adv. 8(eabl9806)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dong Z, Liang X, Wu X, Kang X, Guo Y, Shen
S, Liang J and Guo W: Promoter hypermethylation-mediated
downregulation of tumor suppressor gene SEMA3B and lncRNA
SEMA3B-AS1 correlates with progression and prognosis of esophageal
squamous cell carcinoma. Clin Exp Metastasis. 36:225–241.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gaur P, Bielenberg DR, Samuel S, Bose D,
Zhou Y, Gray MJ, Dallas NA, Fan F, Xia L, Lu J and Ellis LM: Role
of class 3 semaphorins and their receptors in tumor growth and
angiogenesis. Clin Cancer Res. 15:6763–6770. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Varshavsky A, Kessler O, Abramovitch S,
Kigel B, Zaffryar S, Akiri G and Neufeld G: Semaphorin-3B is an
angiogenesis inhibitor that is inactivated by furin-like
pro-protein convertases. Cancer Res. 68:6922–6931. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jialing Z, Qun H, Lifei B and Xiulan S:
Progress in the study of Semaphorin3 antitumor mechanism. J Modern
Oncol. 16:312–314. 2008.
|
|
18
|
Zhou Y, Gunput RA and Pasterkamp RJ:
Semaphorin signaling: Progress made and promises ahead. Trends
Biochem Sci. 33:161–170. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Schwarz Q, Waimey KE, Golding M, Takamatsu
H, Kumanogoh A, Fujisawa H, Cheng HJ and Ruhrberg C: Plexin A3 and
plexin A4 convey semaphorin signals during facial nerve
development. Dev Biol. 324:1–9. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tam KJ, Hui DHF, Lee WW, Dong M, Tombe T,
Jiao IZF, Khosravi S, Takeuchi A, Peacock JW, Ivanova L, et al:
Semaphorin 3 C drives epithelial-to-mesenchymal transition,
invasiveness, and stem-like characteristics in prostate cells. Sci
Rep. 7(11501)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bica C, Tirpe A, Nutu A, Ciocan C, Chira
S, Gurzau ES, Braicu C and Berindan-Neagoe I: Emerging roles and
mechanisms of semaphorins activity in cancer. Life Sci.
318(121499)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tingzhe S: Synergistic effect of
hyperthermia combined with radiotherapy in tumor therapy based on
mathematical model of p53 signal transduction network. J China
Pharmaceutical Univ. 52:361–370. 2021.
|
|
23
|
Rui S, Peixin X and Lin D: Establishment
of a human lung adenocarcinoma A549 cell model knockdown by tumor
suppressor gene p53 and its functional study. Chin J Diagnost
Pathol. 29:323–325. 2022.
|
|
24
|
Jing Y: Expression of p16, p53, Ki-67
protein in cervical carcinoma and its correlation with
clinicopathological features. Clin Med. 44:42–44. 2024.
|
|
25
|
Ochi K, Mori T, Toyama Y, Nakamura Y and
Arakawa H: Identification of semaphorin3B as a direct target of
p53. Neoplasia. 4:82–87. 2002.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chen R, Zhuge X, Huang Z, Lu D, Ye X, Chen
C, Yu J and Lu G: Analysis of SEMA3B methylation and expression
patterns in gastric cancer tissue and cell lines. Oncol Rep.
31:1211–1218. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tang H, Wu Y, Liu M, Qin Y, Wang H, Wang
L, Li S, Zhu H, He Z, Luo J, et al: SEMA3B improves the survival of
patients with esophageal squamous cell carcinoma by upregulating
p53 and p21. Oncol Rep. 36:900–908. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Castro-Rivera E, Ran S, Brekken RA and
Minna JD: Semaphorin 3B inhibits the phosphatidylinositol
3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer
cells. Cancer Res. 68:8295–8303. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung
cancer. Biochem Pharmacol. 90:197–207. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Huang GS, Brouwer-Visser J, Ramirez MJ,
Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER,
Goldberg GL, et al: Insulin-like growth factor 2 expression
modulates Taxol resistance and is a candidate biomarker for reduced
disease-free survival in ovarian cancer. Clin Cancer Res.
16:2999–3010. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sherr CJ and Weber JD: The ARF/p53
pathway. Curr Opin Genet Dev. 10:94–99. 2000.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Rolny C, Capparuccia L, Casazza A, Mazzone
M, Vallario A, Cignetti A, Medico E, Carmeliet P, Comoglio PM and
Tamagnone L: The tumor suppressor semaphorin 3B triggers a
prometastatic program mediated by interleukin 8 and the tumor
microenvironment. J Exp Med. 205:1155–1171. 2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yunyan G and Xilong O: Progress in the
study of the relationship between VEGF165 and VEGF 165b and Tumor.
Modern Med J. 34:447–450. 2006.
|
|
34
|
de Castro Junior G, Puglisi F, de Azambuja
E, El Saghir NS and Awada A: Angiogenesis and cancer: A cross-talk
between basic science and clinical trials (the ‘do ut des’
paradigm). Crit Rev Oncol Hematol. 59:40–50. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Abou Faycal C, Gazzeri S and Eymin B: A
VEGF-A/SOX2/SRSF2 network controls VEGFR1 pre-mRNA alternative
splicing in lung carcinoma cells. Sci Rep. 9(336)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wiszniak S and Schwarz Q: Exploring the
intracrine functions of VEGF-A. Biomolecules. 11(128)2021.DOI:
10.3390/biom11010128.
|
|
37
|
Apte RS, Chen DS and Ferrara N: VEGF in
signaling and disease: Beyond discovery and development. Cell.
176:1248–1264. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chen Y, Mathy NW and Lu H: The role of
VEGF in the diagnosis and treatment of malignant pleural effusion
in patients with non-small cell lung cancer (Review). Mol Med Rep.
17:8019–8030. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Min Z, Liqiang X, Huizhi Y, Nan Y and Guo
W: Expression of VEGF in non-small cell lung cancer and its
correlation with pathological characteristics. J Modern Oncol.
24:3386–3389. 2016.
|
|
40
|
Wang YQ, Chen H, Xu S, Liao CR, Xu A, Han
Y, Yang MH, Zhao L, Hu SS, Wang L, et al: SEMA3B-AS1 suppresses
colorectal carcinoma progression by inhibiting Semaphorin
3B-dependent VEGF signaling pathway activation. MedComm (2020).
4(e365)2023.PubMed/NCBI View
Article : Google Scholar
|
|
41
|
Castro-Rivera E, Ran S, Thorpe P and Minna
JD: Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast
cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci
USA. 101:11432–11437. 2004.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wang K, Ling T, Wu H and Zhang J:
Screening of candidate tumor-suppressor genes in 3p21.3 and
investigation of the methylation of gene promoters in oral squamous
cell carcinoma. Oncol Rep. 29:1175–1182. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pronina IV, Loginov VI, Burdennyy AM,
Fridman MV, Kazubskaya TP, Dmitriev AA and Braga EA: Expression and
DNA methylation alterations of seven cancer-associated 3p genes and
their predicted regulator miRNAs (miR-129-2, miR-9-1) in breast and
ovarian cancers. Gene. 576:483–491. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Guo W, Liang X, Liu L, Guo Y, Shen S,
Liang J and Dong Z: MiR-6872 host gene SEMA3B and its antisense
lncRNA SEMA3B-AS1 function synergistically to suppress gastric
cardia adenocarcinoma progression. Gastric Cancer. 22:705–722.
2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Li K, Chen MK, Li LY, Lu MH, Shao ChK, Su
ZL, He D, Pang J and Gao X: The predictive value of semaphorins 3
expression in biopsies for biochemical recurrence of patients with
low- and intermediate-risk prostate cancer. Neoplasma. 60:683–689.
2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Loginov VI, Dmitriev AA, Senchenko VN,
Pronina IV, Khodyrev DS, Kudryavtseva AV, Krasnov GS, Gerashchenko
GV, Chashchina LI, Kazubskaya TP, et al: Tumor suppressor function
of the SEMA3B gene in human lung and renal cancers. PLoS One.
10(e0123369)2015.PubMed/NCBI View Article : Google Scholar
|
